Trial · NCT05323656
Adverse events168
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 168
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vomiting | Gastrointestinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 4 | 27 | 6 |
| other | Vomiting | Gastrointestinal disorders | Placebo and Pembrolizumab 200 mg | 3 | 28 | 3 |
| other | Dry mouth | Gastrointestinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 3 |
| other | Dry mouth | Gastrointestinal disorders | Placebo and Pembrolizumab 200 mg | 4 | 28 | 4 |
| other | Stomatitis | Gastrointestinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 2 | 27 | 2 |
| other | Stomatitis | Gastrointestinal disorders | Placebo and Pembrolizumab 200 mg | 3 | 28 | 3 |
| other | Dysphagia | Gastrointestinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 3 |
| other | Dysphagia | Gastrointestinal disorders | Placebo and Pembrolizumab 200 mg | 1 | 28 | 1 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 3 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Placebo and Pembrolizumab 200 mg | 0 | 28 | 0 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 7 | 27 | 9 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Placebo and Pembrolizumab 200 mg | 5 | 28 | 6 |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 3 |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Placebo and Pembrolizumab 200 mg | 3 | 28 | 4 |
| other | Skin Lesion | Skin and subcutaneous tissue disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 | 27 | 3 |
| other | Skin Lesion | Skin and subcutaneous tissue disorders | Placebo and Pembrolizumab 200 mg | 1 | 28 | 1 |
| other | Eczema | Skin and subcutaneous tissue disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 0 | 27 | 0 |
| other | Eczema | Skin and subcutaneous tissue disorders | Placebo and Pembrolizumab 200 mg | 3 | 28 | 5 |
| other | Rash | Skin and subcutaneous tissue disorders | Setanaxib 1600 mg and Pembrolizumab 200 mg | 2 | 27 | 2 |
| other | Rash | Skin and subcutaneous tissue disorders | Placebo and Pembrolizumab 200 mg | 1 | 28 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05323656/events?page=2